Director Deborah Taylor Tate filed a Form 4 with the SEC on November 9, 2026, reporting a disposition of 900 shares of HealthStream Inc. common stock on November 6, 2026, via a gift transaction at a price of $0.
Christopher L. Jensen, EVP and Chief People Officer of NXP Semiconductors N.V. (NASDAQ:NXPI), filed a Form 4 on November 9, 2026, disclosing two rounds of restricted stock unit vesting and related tax-withholding share disposals on November 5 and November 7, 2026.
Michael Thomas Hoffmann, EVP and General Counsel of NXP Semiconductors N.V. (NASDAQ:NXPI), filed a Form 4 on November 9, 2026, disclosing restricted stock unit vestings and related share withholdings on November 5 and November 7, 2026.
Rafael Sotomayor, CEO and President of NXP Semiconductors N.V. (NASDAQ:NXPI), filed a Form 4 on November 9, 2026, disclosing restricted stock unit vestings and related share disposals on November 5 and November 7, 2026.
Andrew Hardy, EVP and Chief Sales Officer of NXP Semiconductors N.V. (NASDAQ:NXPI), filed a Form 4 on November 9, 2026, disclosing restricted stock unit vesting events and related share withholdings on November 5 and November 7, 2026.
Neil B. Shah, Chief Commercial Officer of SharkNinja, Inc. (NYSE:SN), filed a Form 4 on November 9, 2026, disclosing the sale of ordinary shares on November 6, 2026, held indirectly through a limited partnership.
Director Anthony R. Foxx filed a Form 4 with the SEC on November 9, 2026, disclosing a charitable gift of 85 shares of NXP Semiconductors N.V. common stock made on November 5, 2026.
NXP Semiconductors N.V. EVP and CFO William Betz filed a Form 4 on November 9, 2026, disclosing two restricted stock unit vesting events and related tax-withholding disposals of common stock on November 5 and November 7, 2026.
Shereen Solaiman, Chief People Officer of Myriad Genetics Inc, filed a statement of changes in beneficial ownership on November 9, 2026, disclosing a grant of 83,049 time-based stock options on November 6, 2026.
Benjamin Richard Wheeler, Chief Financial Officer of Myriad Genetics Inc, filed a Form 4 on November 9, 2026, disclosing the acquisition of a time-based stock option covering 121,379 shares of common stock granted on November 6, 2026.